PIP-2402-1,Gustav-Gram.jpg

Image -

PIP-2402-1,Gustav-Gram.jpg

Bioteknikbolaget Pila Pharma, som är börsnoterat i Sverige, har just tagit in 10 miljoner kronor i en riktad emission för en ny studie rörande fetma. Bolagets grundare och styrelseordförande är den tidigare Novo Nordisk-forskaren Dorte X. Gram, säger Gustav H. Gram, vd för Pila Pharma. Foto: Pila Pharma.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.jpg
Size:
3000 x 2000, 3.04 MB
Download

Related content

Bioteknikbolaget Pila Pharma, som är börsnoterat i Sverige, har just tagit in 10 miljoner kronor i en riktad emission för en ny studie rörande fetma. Foto: Gustav H. Gram, vd för Pila Pharma.

Malmöbaserat bioteknikbolag tar in kapital till ny studie om fetma

Bioteknikbolaget Pila Pharma, som är börsnoterat i Sverige, har just tagit in 10 miljoner kronor i en riktad emission för en ny studie rörande fetma. Bolagets grundare och styrelseordförande är den tidigare Novo Nordisk-forskaren Dorte X. Gram.

Welcome to Epicent Public Relations A/S!

Epicent was founded in 1999 and specializes in press assignments. For five consecutive years, we have been named among Denmark’s fastest growing companies.

Boasting extensive experience in increasing brand awareness, we apply our knowhow and strong editorial networks to ensure optimal execution of PR strategies and multiply clients’ exposure in editorial media. Locally, regionally, nationally and internationally.

Epicent Public Relations A/S

Gåseagervej 12 E
8250 Egå
Denmark

Website
Visit our other newsrooms
Enter your email address to follow Epicent Public Relations A/S

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Epicent Public Relations A/S.

Okay